Clinical Research
Industry Leaders React to Historic Cannabis Rescheduling
President Donald Trump’s executive order directing federal agencies to move cannabis from Schedule I to Schedule III of the Controlled Substances Act represents the most significant shift in US drug policy in over half a century.
